Peak flow in heart failure

ISRCTN	ISRCTN83265463
DOI	https://doi.org/10.1186/ISRCTN83265463
Protocol serial number	N0159093858
Sponsor	Department of Health (UK)
Funder	North Tees and Hartlepool NHS Trust (UK)

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Dr Philip Snashall
Scientific

Professor of Medicine
North Tees & Hartlepool NHS Trust
North Tees General Hospital
Stockton-on-Tees
TS19 8PE
United Kingdom

Primary study design	Interventional
Study design	Randomised double blind trial
Secondary study design	Randomised controlled trial
Scientific title	Peak flow in heart failure
Study objectives	Does treatment with ipratropium bromide (Atrovent) improve peak flow and associated symptoms?
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Cardiovascular: Heart failure
Intervention	Ipratropium bromide vs standard practice
Intervention type	Drug
Phase	Not Applicable
Drug / device / biological / vaccine name(s)	Ipratropium bromide
Primary outcome measure(s)	Improvement in peak flow rates and other symptoms.
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	01/04/2004

Participant type(s)	Patient
Age group	Not Specified
Sex	Not Specified
Key inclusion criteria	Patients with heart failure
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/02/2001
Date of final enrolment	01/04/2004

North Tees & Hartlepool NHS Trust

Stockton-on-Tees
TS19 8PE
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan